RMRobert R. Maronpot

Robert R. Maronpot

*This is an algorithmically generated author record based on publicly available information.

Robert R. Maronpot has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Shim-Mo Hayashi

    National Institute of Health Sciences, Kawasaki, Kanagawa, Japan

    10 shared publications
  • Makoto Shibutani

    Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan.

    6 shared publications
  • Mihoko Koyanagi

    San-Ei Gen F. F. I., Inc., 1-1-11 Sanwa-cho, Toyonaka, Osaka 561-8588, Japan

    6 shared publications
  • Mihoko Koyanagi

    Global Safety and Regulatory Sciences, San-Ei Gen F.F.I., Inc., Osaka 561-8588, Japan

    6 shared publications
  • Shunsuke Ozawa

    Laboratory of Veterinary Pathology, Division of Animal Life Science, Institute of Agriculture Tokyo University of Agriculture and Technology Tokyo Japan

    5 shared publications
  • Ryota Ojiro

    Laboratory of Veterinary Pathology, Division of Animal Life Science, Institute of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan; Cooperative Division of Veterinary Sciences, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan

    4 shared publications

Latest Publications

  • Open Access

    Exposure to alpha-glycosyl isoquercitrin from gestation to adulthood increases synaptic densities of glutamatergic and GABAergic inputs in the hippocampal dentate gyrus in rats

    by Qian Tang, Xinyu Zou, Ryota Ojiro, Shunsuke Ozawa, Mihoko Koyanagi, Robert R. Maronpot, Toshinori Yoshida, Makoto Shibutani


  • Translational Relevance of Rodent Models to Predict Human Liver Disease

    by Debabrata Mahapatra, Robert Maronpot

    Animals models are essential to understand the complex pathobiology of human diseases. George Box’s aphorism based on statistics “All models are wrong, but some are useful” certainly applies to animal models of disease. In this session, the translational relevance of various animal models applicable to human liver disease was explored starting with a historic overview of the rodent cancer bioassay with emphasis on hepatocarcinogenesis from early work at the National Cancer Institute, refinement by the National Toxicology Program and contemporary efforts to identify potential mechanisms and their relevance to human cancer risk. Subsequently, recently elucidated understanding of the molecular drivers and signaling mechanisms of liver pathophysiology and liver cancer, including factors associated with liver regeneration, metabolic hepatocellular zonation, and the role of macrophages and their crosstalk with stellate cells in understanding human liver disease was discussed. Next, our contemporary understanding of the role of nuclear receptors in hepatic homeostasis and drug response highlighting nuclear receptor activation and crosstalk in modulating biological responses associated with liver damage and neoplastic response were discussed. Finally, an overview and translational relevance of different drug-induced liver injury (DILI) rodent model systems focused on pathology and mechanisms with commentary on current relevant Food and Drug Administration (FDA) perspective were summarized with closing remarks.

  • Exploring the effects of embryonic and neonatal exposure to lipopolysaccharides on oligodendrocyte differentiation in the rat hippocampus and the protective effect of alpha-glycosyl isoquercitrin

    by Hiromu Okano, Ryota Ojiro, Xinyu Zou, Qian Tang, Shunsuke Ozawa, Mihoko Koyanagi, Robert R. Maronpot, Toshinori Yoshida, Makoto Shibutani

  • Oral chronic toxicity and carcinogenicity study of alpha-glycosyl isoquercitrin (AGIQ) in Sprague Dawley rats

    by Robert Maronpot, Yuval Ramot, Abraham Nyska, Christopher Sproul, Rebecca Moore, Brad Bolon, Shim-Mo Hayashi


  • Open Access

    Gardenia blue is not carcinogenic in the rasH2 mouse

    by Robert R Maronpot, Mihoko Koyanagi, Shim-Mo Hayashi, Debabrata Mahapatra, Masayuki Nishino, Minoru Iniwa

    Introduction: Gardenia blue is currently being considered as a naturally derived food colorant for use in the global marketplace. Methods: To assess its carcinogenic potential, 100 female and 100 male CByB6F1-Tg (HRAS)2Jic (rasH2) mice were allocated to four dose groups and exposed to gardenia blue in the diet for 26 weeks at dose levels of 0.0% (control), 0.5%, 2.5%, or 5.0% (corresponding to 0.0, 664.8, 3341.0, and 6623.2 mg/kg/day in male mice and 0.0, 1182.7, 5561.1, and 10,440.3 mg/kg/day in female mice, respectively). An additional group of 10 males and 10 females was administered intraperitoneal N-methyl-N-nitrosourea (MNU) as a positive control. Clinical observations, body and organ weights, clinical chemistry, hematology, and hormone analyses were performed in addition to urinalysis and histopathology. Results: The positive control elicited expected responses specific to rasH2 mice. There were sporadic background non-dose-related findings in clinical pathology parameters and anatomic pathology common to rasH2 mice in the absence of any gardenia blue induced dose-related changes. Discussion: Under these study conditions, the no-observed-adverse-effect level was 5% gardenia blue (6623.2 mg/kg/day in male mice and 10,440.3 mg/kg/day in female mice). Conclusions: Based on this study a high dietary level of gardenia blue was negative for carcinogenicity in the rasH2 mouse test system.


  • Open Access

    Prenatal developmental toxicity of gardenia blue, a natural food colorant, in rats and rabbits

    by William J Breslin, Jaime L Mesnard, Robert R Maronpot, Mihoko Koyanagi, Shuichi Chiba, Masayuki Nishino, Shim-Mo Hayashi

    Introduction: Gardenia blue is a colorant widely used in Asia in food and beverages. The objectives of the present studies were to evaluate the maternal and prenatal embryo-fetal developmental toxicity of gardenia blue in rats and rabbits. Methods: Sprague Dawley rats and New Zealand White rabbits were administered gardenia blue daily by oral gavage at doses of 0 (deionized water vehicle), 500, 1000 or 2000 mg/kg/day on Gestation Days 6 through 20 (rats) and 7 through 28 (rabbits). Endpoints evaluated included clinical observations, body weight, food consumption, thyroid hormones (rats), thyroid weights and histopathology (rats), gross pathologic changes, ovarian and uterine observations, fetal weight and anogenital distance (rats) and fetal morphology (external, visceral and skeletal). Results: Treatment related maternal findings attributed to the blue/dark color of the test substance included body surface staining, and dark/blue discoloration of the kidneys, gastrointestinal track and mesenteric lymph nodes at all or most doses in the rat and/or rabbit. Slight reductions in food consumption without effects on body weight were also observed in rats at all doses and in rabbits at 2000 mg/kg/day. There were no treatment related effects on maintenance of pregnancy, postimplantation loss, litter size, fetal weight and anogenital distance, or fetal external, visceral, or skeletal malformations and variations. Conclusions: Based on these results, the maternal and developmental no-observed-adverse-effect level for gardenia blue in rats and rabbits was ≥2000 mg/kg/day.


  • Open Access

    Twelve-month in utero safety assessment of gardenia blue, a natural food colorant

    by Robert R. Maronpot, Michael Streicker, Debabrata Mahapatra, Rebecca Moore, Mihoko Koyanagi, Shuichi Chiba, Masayuki Nishino, Shim-Mo Hayashi

    Toxicity assessment of the food colorant Gardenia jasminoides Ellis at dietary exposures of 0.0%, 0.1%, 0.5%, 1.5%, 3.0% and 5.0% included measures of T-cell- dependent antibody response, neurotoxicity, and clinical and anatomic pathology in Sprague Dawley rats during mating, gestation, lactation, postnatal development, and following weaning for up to 12 months including 3- and 6-month interim evaluations. Blue coloration of the gastrointestinal tract, mesenteric lymph nodes and kidneys was present in treated rats only at necropsy with minimal blue coloration at the lowest dose and without histopathological correlates in any of the tissues. There was good survival with no consistent treatment-related changes in hematology, clinical chemistry, enhanced evaluation of lymphoid tissues, or tissue histopathology at interim and final time points. T-cell dependent antibody response and neurotoxicity screening were negative in treated rats. The no-observed-adverse-effect level (NOAEL) was determined to be 5.0% gardenia blue (2,854.5 and 3,465.4 mg/kg/day in parental males and females, respectively, prior to mating; 3,113.5 and 4,049.6 mg/kg/day in male and female offspring, respectively, following up to 12 months of exposure.


  • Continuous exposure to alpha-glycosyl isoquercitrin from mid-gestation ameliorates polyinosinic-polycytidylic acid-disrupted hippocampal neurogenesis in rats

    by Kazumi Takashima, Hiromu Okano, Ryota Ojiro, Qian Tang, Yasunori Takahashi, Shunsuke Ozawa, Xinyu Zou, Mihoko Koyanagi, Robert R. Maronpot, Toshinori Yoshida, et al.


  • Progressive disruption of neurodevelopment by mid‐gestation exposure to lipopolysaccharides and the ameliorating effect of continuous alpha‐glycosyl isoquercitrin treatment

    by Hiromu Okano, Kazumi Takashima, Yasunori Takahashi, Ryota Ojiro, Qian Tang, Shunsuke Ozawa, Xinyu Zou, Mihoko Koyanagi, Robert R. Maronpot, Toshinori Yoshida, et al.

    We investigated the effect of lipopolysaccharide (LPS)‐induced maternal immune activation used as a model for producing neurodevelopmental disorders on hippocampal neurogenesis and behaviors in rat offspring by exploring the antioxidant effects of alpha‐glycosyl isoquercitrin (AGIQ). Pregnant Sprague–Dawley rats were intraperitoneally injected with LPS (50 μg/kg body weight) at gestational days 15 and 16. AGIQ was administered in the diet to dams at 0.5% (w/w) from gestational day 10 until weaning at postnatal day 21 and then to offspring until adulthood at postnatal day 77. During postnatal life, offspring of LPS‐injected animals did not show neuroinflammation or oxidative stress in the brain. At weaning, LPS decreased the numbers of type‐2b neural progenitor cells (NPCs) and PCNA+ proliferating cells in the subgranular zone, FOS‐expressing granule cells, and GAD67+ hilar interneurons in the dentate gyrus. In adulthood, LPS decreased type‐1 neural stem cells, type‐2a NPCs, and GAD67+ hilar interneurons, and downregulated Dpysl3, Sst, Fos, Mapk1, Mapk3, Grin2a, Grin2b, Bdnf, and Ntrk2. In adults, LPS suppressed locomotor activity in the open field test and suppressed fear memory acquisition and fear extinction learning in the contextual fear conditioning test. These results indicate that mid‐gestation LPS injections disrupt programming of normal neurodevelopment resulting in progressive suppression of hippocampal neurogenesis and synaptic plasticity of newborn granule cells by suppressing GABAergic and glutamatergic neurotransmitter signals and BDNF/TrkB signaling to result in adult‐stage behavioral deficits. AGIQ ameliorated most aberrations in hippocampal neurogenesis and synaptic plasticity, as well as behavioral deficits. Effective amelioration by continuous AGIQ treatment starting before LPS injections may reflect both anti‐inflammatory and anti‐oxidative stress effects during gestation and neuroprotective effects of continuous exposure through adulthood.


  • Open Access

    Lack of skin sensitization hazard potential for alpha-glycosyl isoquercitrin (AGIQ) utilizing the Local Lymph Node Assay

    by Puneet Vij, Douglas A. Donahue, Keith P. Burke, Shim-Mo Hayashi, Robert R. Maronpot